cervicalcancerbreastcancerq1yanxietywomenage 55-64 y.o.20%cardiovasculardisease≥ 200mg/dL40-59 y.o.,ASCVD ≥10%, lowbleeding riskaspirin40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor≥ 100mg/dL40y.o.q15yHepatitisB52y.o.colorectalcancerPREVENTequation< 60y.o.Timedup andgo testdiabetesstatinpneumococcal≥ 126mg/dLovariancancer75y.o.hormonetherapydepressionlungcancerq2ymultidoseinitial series,then 1 doseat 2-6monthstobaccouseFractureRiskAssessmentToolHIV3%aromataseinhibitorsHepatitisCoverweight/ obesityq2ycommunity-dwelling,postmenopausalwomen≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorstamoxifenq1ymammogram65y.o.dementia6.5%1 dose; 2doses (2-6monthsapart) ifimmunocomphypertensionq3yTyrer-Cuzickmodel60y.o.≥ 140mg/dL2 doses,2-6monthsapart5.7%raloxifeneq1-2ymammogrambased on lifeexpectancy /health statusherpeszosterdyslipidemia50y.o.40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors40-70 y.o.,ASCVD ≥10%, lowbleeding riskq5yGailmodelinsufficientevidenceforscreening40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorcervicalcancerbreastcancerq1yanxietywomenage 55-64 y.o.20%cardiovasculardisease≥ 200mg/dL40-59 y.o.,ASCVD ≥10%, lowbleeding riskaspirin40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor≥ 100mg/dL40y.o.q15yHepatitisB52y.o.colorectalcancerPREVENTequation< 60y.o.Timedup andgo testdiabetesstatinpneumococcal≥ 126mg/dLovariancancer75y.o.hormonetherapydepressionlungcancerq2ymultidoseinitial series,then 1 doseat 2-6monthstobaccouseFractureRiskAssessmentToolHIV3%aromataseinhibitorsHepatitisCoverweight/ obesityq2ycommunity-dwelling,postmenopausalwomen≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorstamoxifenq1ymammogram65y.o.dementia6.5%1 dose; 2doses (2-6monthsapart) ifimmunocomphypertensionq3yTyrer-Cuzickmodel60y.o.≥ 140mg/dL2 doses,2-6monthsapart5.7%raloxifeneq1-2ymammogrambased on lifeexpectancy /health statusherpeszosterdyslipidemia50y.o.40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors40-70 y.o.,ASCVD ≥10%, lowbleeding riskq5yGailmodelinsufficientevidenceforscreening40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factor

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. cervical cancer
  2. breast cancer
  3. q1y
  4. anxiety
  5. women age 55-64 y.o.
  6. ≥ 20%
  7. cardiovascular disease
  8. ≥ 200 mg/dL
  9. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  10. aspirin
  11. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  12. ≥ 100 mg/dL
  13. 40 y.o.
  14. q15y
  15. Hepatitis B
  16. 52 y.o.
  17. colorectal cancer
  18. PREVENT equation
  19. < 60 y.o.
  20. Timed up and go test
  21. diabetes
  22. statin
  23. pneumococcal
  24. ≥ 126 mg/dL
  25. ovarian cancer
  26. 75 y.o.
  27. hormone therapy
  28. depression
  29. lung cancer
  30. ≤ q2y
  31. multidose initial series, then 1 dose at 2-6 months
  32. tobacco use
  33. Fracture Risk Assessment Tool
  34. HIV
  35. 3%
  36. aromatase inhibitors
  37. Hepatitis C
  38. overweight / obesity
  39. q2y
  40. community-dwelling, postmenopausal women
  41. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  42. tamoxifen
  43. q1y mammogram
  44. 65 y.o.
  45. dementia
  46. ≥ 6.5%
  47. 1 dose; 2 doses (2-6 months apart) if immunocomp
  48. hypertension
  49. q3y
  50. Tyrer-Cuzick model
  51. 60 y.o.
  52. ≥ 140 mg/dL
  53. 2 doses, 2-6 months apart
  54. ≥ 5.7%
  55. raloxifene
  56. q1-2y mammogram based on life expectancy / health status
  57. herpes zoster
  58. dyslipidemia
  59. 50 y.o.
  60. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  61. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  62. q5y
  63. Gail model
  64. insufficient evidence for screening
  65. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor